Migraine has been deemed the “forgotten epidemic.” As a common neurological disease, it imposes a significant personal burden on a migraine sufferer’s quality of life. The incidence of migraine has been shown to be the third most prevalent illness worldwide but migraine often remains undertreated. According to the Migraine Research Foundation, more than half of all migraine sufferers are undiagnosed.
There is an overwhelming need for treatment of this major health condition. Current treatments can provide relief, but new treatment innovations are now becoming available to provide viable options, including for episodic migraine.
This program is made possible through educational support from AbbVie.